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INTRODUCTION 
Chronic kidney disease is defined as the presence of kidney 
damage or a decreased level of kidney function, for a period of three 
months or more .It can be divided into five stages depending upon how 
severe is the damage to kidneys or the level of decrease in renal 
function.In many renal diseases, the damage can be ascertained by the 
presence of Albuminuria, defined as albumin-creatinine  ratio>30 mg /g 
in two of three spot urine collections.According to the level of GFR, 
Chronic kidney disease is divided  into five stages.                                    
Epidemiology of chronic kidney disease  
According to a report based on Atherosclerosis risk in communities 
study (ARIC)1,the incidence rate of CKD was 10,350 per 1 million person 
years, when incident CKD was defined as the MDRD estimated GFR of 
less than 60 ml/min/1.73 m2
The best data source for determining CKD prevalence has been the 
national health and nutrition examination survey in the united states 
(NHANES), according to which the prevalence was two order magnitude 
larger than the incident CKD patients
. 
2
In India there is no longitudinal study and there is limited data on 
the prevalence of CKD. 
. 
Agarwal et al studied south delhi urban population & reported the 
prevalence of stage 4  CKD to be  0.785 %. 
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Singh et al studied the prevalence of stage 5 CKD to be 4.2 % in 
both urban and semi urban population of Delhi. 
In a recently published screening & early evaluation of Kidney 
Disease study, the prevalence of CKD according to various stages was 
studied and it was 7 %, 4.3%,4.4%,0.8%& 0.8 % respectively for stages 
I,II,III, IV, & V. 
TABLE -1 
STAGING OF CHRONIC KIDNEY DISEASE (national kidney 
foundation)
STAGE 
2 
DESCRIPTION GFR/ml/min/1.73m2 
1 Kidney damage with normal 
or  GFR 
≥90 
2 Kidney damage with mild  
reduction in GFR 
60-89 
3 Moderate reduction in GFR 30-59 
4 Severe reduction in  GFR 15-29 
5 Kidney failure <15 or dialysis. 
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CKD, prevalence is complicated with difference in calibration of 
creatinine measurements.3,4. In late 2000’s the same blood sample 
creatinine measurements differed by 0.2 or 0.3 mg/dl5. 
In the past 2 decades of NHANES  surveys. creatinine has been 
measured in which different methods were used and systemic biases were 
introduced. Thus there was an apparent increase in prevalence of CKD 
from the period 1988 to 1994 to the period 1999 to 20046,7 
RISK FACTORS AND CAUSES OF CKD; 
• The most common cause of CKD is Diabetic Nephropathy 
worldwide8 . 
• Hypertension is an important factor in the progression of CKD. 
• Obesity is associated with hypertension, proteinuria and  
progressive renal disease9,10 
• Metabolic syndrome has got an increased risk 11 of CKD. 
• Complications of pregnancy especially preeclampsia causes renal 
damage. 
•  Renal disease progression12 is accelerated by high protein diet. 
• CKD is also associated with substantial increase in the risk of 
cardiovascular disease13. 
Among primary renal diseases autosomal dominant polycystic 
kidney disease was an independent predictor of a greater rate of GFR 
decline14. 
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• Anaemia resulting from inherited  hemoglobinopathy is associated 
with increased renal plasma flow, glomerular hyperfiltration and 
subsequent development of proteinuria, hypertension and ESKD15. 
• In Several studies, elevated levels of low density  lipoprotein 
cholesterol (LDL ) to High density lipoprotein cholesterol16 and 
low HDL cholesterol levels17  have been identified as  both 
susceptibility  and progression risk factor for CKD. 
• Hyperuricemia is an  independent risk factor for increased  serum 
creatinine concentration 18. 
It is also proposed that a small protein, neutrophil gelatinase 
associated lipocalin  released by renal tubules in response to injury ,is an 
early marker which is elevated in proportion to the extent of renal damage 
in patients with CKD19,20. 
OTHER RISK FACTORS 
 Cigarette smoking21 
 Alcohol consumption22 
 Use of heroin,cocaine and other psychedelic drugs 23 
 Amyloidosis24 
 Analgesic nephropathy 
 Lead toxicity characterised by chronic interstitial nephritis25 
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DEMOGRAPHIC VARIABLES 
 AGE; CKD increases with age since nephron loss is a part of 
normal ageing.26 
 GENDER; United states renal data system shows increased 
incidence of CKD among males27. 
 ETHNICITY; There is higher incidence among African 
Americans28,29 
 HEREDITORY FACTORS; Among 25,883 patients with incident 
CKD,22.8% reported family history30.thus autosomal dominant 
polycystic kidney disease , Alports  disease, Fabrys disease and 
congenital nephrotic syndrome account for a significant number of 
CKD cases. 
 HEMODYNAMIC FACTORS; There were several studies which 
showed glomerular  hypertension and hyperfiltration causing 
nephron loss 31 and chronic hyperglycemia32 play crucial role in 
establishing CKD. 
 DECREASED NEPHRON NUMBER; According to some autopsy 
studies ,there existed  association between nephron number with 
both hypertension33 and glomerulosclerosis34 
Also, LBW is directly associated with  reduced nephron number35 
and its an independent risk factor. 
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ACQUIRED NEPHRON DEFICIT 
Removal of one of two normal kidney (uninephrectomy) 
predisposes individuals to other forms of CKD36 
  Acute kidney injury is also an important risk factor for CKD. 
PATHOPHYSIOLOGY OF UREMIA 
“Uremia is defined as the illness that would remain if the 
extracellular volume & inorganic ion concentrations were kept normal 
and the renal synthetic products ex.Erythropoietin were replaced in 
patients without kidneys”. Its caused by accumulation of organic waste 
products which are usually excreted by kidneys. In most cited studies 
Johnson and colleagues37 discovered that initiation of hemodialysis 
improved uremic symptoms. 
Increased concentration of plasma urea cause ill effects by 
promoting carbomylation38 
Increased ammonia production is a consequence of urea 
concentration . 
Plasma level of D aminoacids increase in chronic kidney disease39 
Proteins like β2 Microglobulin and cystatin C with molecular 
weight 10 to 20 kDa are normally filtered by the glomerulus &hydrolysed 
in  proximal tubular lysosomes.Their levels rise in proportion to 
creatinine levels as kidney fails. 
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HEMODIALYSIS 
HD prolongs  life for around 1 million patients throughout world, 
without which many would not survive more than few weeks40 . 
Graham (1805-1869) ,a Scottish chemistry professor invented the 
process of separating solutes invitro using semipermeable membranes & 
coined the term “Dialysis”.41 
      “Abel” was the first to use the term artificial kidney42 
In 1944, William kolff used extracorporeal dialysis to support 
patients with acute kidney failure43. 
Incidence and prevalence 
According to US renal data system 5,35,160   patients in US had 
ESKD at the end of 2008.Of these 30 % had transplants & the rest were 
managed with dialysis. Highest prevalence of CKD was in Taiwan. 
Statistics from USRDS ,states  for patients starting dialysis in 2000 
through 2001 show a 79% I year survival,65 % 2 year survival and 38 % 
5 year survival44 
According to current clinical practice dialysis can be commenced 
at an estimated GFR of less than 10 ml/min/1.73m2. 45 
Vascular access; 
Brescia and colleagues46 eloborated the procedure to create an AV 
fistula in 1996 marking the viability of HD as a long term therapy for 
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CKD .Arm is the preferred site for fistula and grafts .In some patients ,leg 
is the preferred site47 
The radiocephalic AV fistula is the access of choice for stage 5 
CKD patients. 
Types of vascular access;  
a) AV fistulas are created by connecting vein to artery and the two 
vessels must be in proximity to each other 
b) Vascular approach using ePTFE is the most prominent type of 
vascular access in United States. 
 Some small trials suggested fish oil use is effective in reducing 
thrombosis in grafts48  
 Another study supported the use of low dose Aspirin and 
Dipyridamole after placement of AV Grafts49 
General principles of Hemodialysis 
 Therapeutically in hemodialysis solutes are removed essentially by 
diffusion and to a lesser extent by convection across a semipermeable 
membrane. The goals of dialysis are removal of accumulative fluid and 
toxic substances and the performance is analysed by clearance of the 
representative solutes. 
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Components of extracorporeal circuit 
 Modern HD machines have the size of a three to four drawer filing 
cabinet. Central to the system is the dialyzer or artificial kidney through 
which exchange between blood and dialysate occurs. 
Blood circuit 
 During dialysis, the steady blood flow is obtained from a central 
venous catheter or from an AV Fistula or graft. 
 If a catheter is used, blood enters the extracorporeal circuit along 
the sides of double lumen catheter (arterial lumen) and return through the 
venous lumen. 
 An alternate dialysate delivery system uses a single needle in the 
vascular access or a single lumen catheter for dialysis50 
Hemodialyzers 
 A Hemodialyzer called as an artificial kidney allows the flow of 
blood and dialysate preferably in opposite directions, through individual 
components separated by a semipermeable membrane. Conventionally 
blood which enters the hemodialyzer is arterial and the blood leaving 
hemodialyser is venous. 
Dialysate circuit 
 Another function of the HD system is the preparation and delivery 
of dialysate to the dialyser. During HD, blood flows in one direction  and 
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the isoosmotic dialysate flows in the opposite direction in the dialysate 
compartment. The temperature of dialysate is maintained between 35o to 
37oc at the inlet. 
Initiation of Dialysis  
 Dialysis is initiated in patients who lose weight and who have 
volume overload and uncontrolled acidosis or hyperkalemia.  
 Incision: After administering prophylactic antibiotics, Gibson 
incision which is made in the lower abdomen is extended to the flank or 
up to even 12th rib. Most of the time, right side is preferred owing to the 
accessibility of the iliac vein ,which makes the operation easier. 
Long term complication of Dialysis51 
 A) Vascular disease 
 B) Anemia 
 C) Renal osteodystrophy 
 D) Uremic neuropathy 
 E) Dialysis access failure 
RENAL TRANPLANTATION 
 A successful renal transplant restores not merely life but also an 
acceptable quality of life to patients. 
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 “Transplantation of kidney for renal failure was done as long as 
ago in 1945, when 3 young surgeons at peter bent hospital in Boston 
namely CHARLES HUFNAGEL, ERNEST LANDSTEINER and 
DAVID HUME  joined the vessels of a cadaver kidney to brachial vessels 
of a young lady with CKD. 
 In 1954,the first successful kidney transplant was performed by 
late Joeseph murray at the peter bent hospital ,Boston. 
 On 1954, December 23rd the first twin to twin kidney transplant 
was done by boston52 
Renal transplant operation and its surgical complications 
 It’s an elective surgical procedure performed in patients who have 
undergone careful preoperative assessment .The main goal is to prevent 
and limit the progression of CKD. 
Operative technique 
 Meticulous surgical skill and techniques , strict aseptic procedure 
& perfect hemostasis are the basic requirements. It involves both vascular 
and ureteric anastamoses. Prior to transplantation proper history and 
physical examination are required to ensure that there is no 
contraindication to surgery. Prophylactic antibiotics are usually given to 
cover Skin infections & urinary tract contaminants53. 
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Post transplantation 
 Provided the graft function is adequate, after transplantation the 
peritoneal dialysis catheter could be capped off & left. The catheter is 
removed after 3 months if the kidney function is stable. When there is 
graft failure within 3 months, the catheter has to be flushed to remove 
debris and fibrin. A successful outcome following a renal transplant 
depends on the early perioperative management. 
 Main factors which affect the long term outcome are delayed graft 
function, acute rejection, early surgical complication like hematuria, urine 
leak, renal vein thrombosis.post operative haemorrhage and lymphocele. 
PHYSIOLOGICAL ANATOMY OF EAR   
Fig :1 Schematic diagram of anatomy of ear 
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The peripheral auditory apparatus is the ear which can be divided 
into external ear, middle ear and internal ear60. 
External ear includes pinna, external auditory meatus and auditory 
canal. 
The external ear is separated from the middle ear by tympanic 
membrane and the middle ear contains three ossicles namely malleus, 
incus and stapes 
The tympanic membrane with the three ossicles act as the 
impedance matching device 
Fig:2 Schematic diagram of inner ear 
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The inner ear includes bony and membranous labyrinths.60  cochlea 
and vestibular apparatus are formed from bony and membranous 
labyrinths. 
The neural apparatus responsible for transduction of sound is the 
organ of Corti which is within the cochlea. 
Vestibular apparatus is composed of 3 semicircular canals namely 
horizontal, superior and posterior canals and 2 otolith organs utricle and 
saccule maintenance of equilibrium and posture 
MECHANISM OF HEARING 
Fig 3:Schematic diagram of organ of corti 
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Sound waves are transmitted from the external ear to the internal 
ear primarily through tympanic membrane causing  vibration of stapes61. 
From tympanic membrane, sound waves are transmitted through air of 
middle ear cavity to reach scala tympani. This is air conduction. 
Bone conduction is the transmission of sound waves from 
environment through the bones which reach the inner ear. 
Sound waves get transmitted from footplate of stapes to the inner 
ear→ movement of stapes inward and outward →.movement of oval 
window→pressure in the perilymph of scala vestibuli increases 
→depression of reissners membrane →depression of basilar membrane 
→pressure wave transmitted to the perilymph of scala tympani→  
outward  movement of round window into the middle ear61. 
When the stapes move outward ..basilar membrane bulges and 
round window is pulled inward. 
TRANSDUCTION OF SOUND WAVES 
In resting state ,ear records 2 potentials. 
RMP of the hair cells and endocochlear potentials 
The basolateral RMP of hair cell is -60 mv. It is due to k efflux. 
The hair cell, being a mechanoreceptor is very sensitive to the 
degree of movement of cilia. The lateral bending of shorter stereocilia 
towards taller cilia is the appropriate stimulus, which open the cation 
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channels, allowing k entry and ca entry into hair cel→. This causes 
depolarisation and increased opening of calcium channels → release of 
neurotransmitter from the synaptic cleft→ . generation of action 
potential→ When stereocilia are pushed away from taller cilia, the 
transduction channels close resulting in hyperpolarisation. 
Hence, both depolarisation and hyperpolarisation depend upon 
movement of hairs. 
 
AUDITORY PATHWAY 
1) Nerve fibres from the spiral ganglion of corti enter the dorsal and 
ventral cochlear nuclei62 
2) From cochlear nuclei  second order neurons pass to the opposite 
side and terminate in the superior olivary nucleus.  
3) From Superior olivary nucleus third order neurons pass upward 
through the lateral leminisci to inferior colliculi of both sides 
4) Fibres from lateral leminisci bypass and pass to the medial 
geniculate body 
5) Fibres from MGB pass to the auditory cortex located in the 
superior temporal gyrus (area 41) & upper part of Sylvian fissure 
which includes both parietal and frontal opercula. 
6) Primary auditory association areas; area 22,21 &20 
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a) Area 22 is the WERNICKE’S area located in the superior temporal 
gyrus61. It is concerned with understanding of auditory and visual 
information. 
b) Area 21 &20 are located in middle and inferior temporal gyrus 
which interpret auditory short term memory. 
Fig 4: Schematic diagram of auditory pathway 
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BIOPHYSICS 
Nerve cell membrane have an equal distribution of positive ions 
outside and negative  ions inside cell membrane. The action potential is 
due to the movement of Na+ & K+  Ions which is responsible for flow 
along cell membrane and is resisted by an intervening tissue  which is 
called impedance. 
1. ELECTRODES 
There are 3 types of electrodes, active reference and ground which 
are made up of platinum, stainless steel, gold .The action potential is 
recorded between active and reference electrode and the ground electrode 
works as a zero voltage reference point. 
Surface and needle electrodes are used in clinical practice. 
2. AMPLIFIER 
A 5 X 10 folds amplification is needed as the biological signals are 
very small and there exists an intrinsic impedance of the electrode and an 
impedance between the electrode and skin which reduce the amplitude of 
the signals. 
3. FILTER 
It is a device which restricts the frequency range of signals and is 
needed for elimination of noise and bringing out the optimal  
characteristics of  waveforms. 
  
 
19 
4. AVERAGER 
It is a device which extracts very small signals for example, evoked 
potentials are burried in EEG noise and sensory nerve action potential in 
EMG noise. 
5. DISPLAY 
The waveforms are displayed in two methods 
i) Analogue oscilloscope display where the action potentials are 
displayed directly following amplification and filtering. 
ii) Computer based digital video display where an analogue digital 
converter and a digital processing technique are used. Hence 
,the signals can be redisplayed with greater sensitivity without 
losing  accuracy of waveforms. 
6. STIMULATOR 
Electrical and magnetic stimulators are used in general Constant 
current type of electrical stimulator delivers constant current to the 
subject over a wide range of electrode impedance whereas a constant 
voltage type of electrical stimulator delivers a fixed voltage between 
anode and cathode. 
Magnetic stimulator are used for noninvasive stimulation of motor 
cortex, peripheral nerves and spinal cord. 
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7. SENSITIVITY SWEEP SPEED 
If the sensitivity is high, the latency of action potential shortens 
and increase in sweep speed also shortens the latency. 
BRAINSTEM AUDITORY EVOKED POTENTIAL 
The brainstem auditory evoked potentials are a series of potentials 
generated by sequential activation of different parts of auditory 
pathway63.They are produced within 10 m.sec by a brief click stimuli. 
Clinical significance of BAEP’S63; 
1) To assess the degree of hearing loss. 
2) To assess the hearing in infants and young children suspected of 
 being deaf. 
3) The latencies and interpeak latencies provide information about 
tumours , in demyelination and in various drug induced traumatic  
disease processes. 
 ANATOMICAL &PHYSIOLOGICAL BASIS OF BAEPS 
Organ of corti, rests upon the Cochlea with its receptor elements 
and hair cells. High frequency signals have impact on the basal end of 
Cochlea& low frequency sounds affect the apical end. 
When cochlea is stimulated, the fibres of 8th nerve which innervate 
the basilar membrane are set into vibration. The 8th nerve neurons situated 
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in the spiral ganglia are bipolar,their axons reach the cochlear nucleus 
whereas dendrites go to hair cells. 
There are three Subnuclei in the cochlear nucleus 
 Anterior Ventral Cochlear Nucleus ( AVCN) 
 Posterior Ventral Cochlear Nucleus ( PVCN) 
 Dorsal Cochlear Nucleus. 
 The Radiations from AVCN pass  through  the Ventral acoustic striae & 
the output from PVCN travel through middle and ventral Acoustic Striae  
to get terminated in the Superior Olivary Nuclei and Inferior Colliculus. 
The output from DCN reach the Superior Olivary Nucleus via the Dorsal 
striae. 
The impulses from the Inferior Colliculi reach the Auditory Cortex via 
the Medial geniculate body. 
         
Fig 5: BAEP WAVEFORM 
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BRAINSTEM ELECTRICAL ACTIVITY AND ITS 
CORRELATION WITH BAEP 
 In first 10 ms after a brief acoustic stimuli, a series of potentials which 
corresponds to sequential activation of the peripheral, pontomedullary, 
pontine and midbrain portions of the auditory pathway are recorded. 
The origin of the waveforms are, 
Wave I : From the peripheral part of 8th cranial nerve  
    adjacent to cochlea. 
Wave II : From the Cochlear nuclei 
Wave III : From the Superior olivary nucleus. 
Wave IV : From the Lateral lemniscus 
Wave V : From Inferior colliculi. 
Wave VI : From medial geniculate body 
Wave VII : From auditory cortex     
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Fig 6: ORIGIN OF BAEP WAVEFORM 
 
Fig 7: RECORDED BAEP WAVEFORMS 
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FACTORS AFFECTING BAEP WAVEFORMS 
1. The latency of BAEP waveforms is age dependant up to two years. 
Older adults have prolonged I to IV interpeak latency compared to 
younger persons.64 
2. Females have high amplitude and short latency waveforms. 
3. The latency of BAEP waveforms decreases with increased 
temperature and increases with decreased temperature 
4. Certain drugs like barbiturates and alcohol prolong the wave V 
latency by decreasing the body temperature and they do not 
directly act on the auditory pathway.64 
5. Any hearing deficit should be ruled out prior to recording BERA. 
CHARACTERISTICS OF WAVEFORMS OF BAEP 
WAVE I: It is the first up going peak which appears 1.4 ms after the 
stimulus. The amplitude of the wave can be increased by 
using horizontal montage and an external canal needle 
electrode..As it originates from the 8th nerve, this wave is 
preserved in patients with CNS problem alone. It is absent or 
reduced in patients with peripheral hearing impairment. 
WAVE II: It is a poorly defined wave, which is absent in cochlear 
nucleus lesions 
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WAVE III: It is a prominent upgoing peak which appears as a bifid 
wave. It is reduced in superior olivary nuclear lesions 
WAVE IV: It is a small wave which appears in the upgoing phase of 
wave V. It is absent in lateral leminisci lesions. 
WAVE V: It is the most prominent peak which appears 5.5 ms after the 
auditory click. It disappears in inferior colliculi lesions. 
Abnormal BAEP recordings are seen in 
a) Absence of wave I is seen in 8th nerve tumour and ischaemia. 
b) Absence of waves beyond wave I is seen in acoustic neuroma, 
meningioma. 
c) Absence of waves 1V & V is seen in conditions like multiple 
sclerosis, hydrocephalus. 
BAEP  WAVEFORMS  MEASUREMENT 
The parameters used for analysing the BAEP Waveforms are  
A) Absolute latency & amplitude 
B) Interpeak latencies(I-III,I-V,III-V) 
C) Amplitude ratio of V/I 
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Absolute latency & amplitude 
 Amplitude is measured as the height from the peak of a wave to the 
trough of the same wave & latency expressed in ms is measured from the 
beginning of the first wave to the peak of that wave. 
Inter peak latencies 
 The commonly measured interpeak latencies are I-III,I-V & III-V. 
I-V Inter peak latency 
 It indicates signal transduction from the proximal part of the eighth 
nerve to midbrain through pons. It has a normal value of 4.5 ms. It is 
prolonged in elderly males and in conditions like Demyelination, 
Degenerative diseases and Hypoxic brain damage. 
I-III Interpeak latency 
It measures the conduction of auditory radiation from the eighth nerve 
across the subarachnoid space to lower pons. It has a normal value of 2.5 
ms and its prolonged in eighth nerve tumour, Guillain barre syndrome or 
any pontomedullary junction diseases. 
III-V Interpeak latency 
 It denotes the conduction of impulses from lower pons to midbrain. 
It has a normal value of 2.4 ms .Its isolated prolongation is not significant 
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Amplitude ratio of V/I 
 This helps to assess whether the hearing impairment is  peripheral 
or central.. 
 Sohmer54 et al in the year 1967 first recorded Auditory Brainstem 
Responses with surface electrodes. 
 Jewett55 et al in the year 1971, interpreted BAEP recordings from 
the Absolute peak latencies and Interpeak Latencies. 
 Selters56 et al in 1977, produced landmark findings of prolonged  
Inter peak latencies in tumour cases.  
 Hecox57 et al stated that ABR could be used as a measuring tool for 
estimating hearing threshold in adults and infants. 
 It was Starr58 et al in 1975 who first reported abnormal ABR 
findings due to central nervous system pathology in brainstem. 
 Sensorineuronal hearing loss has been documented in CKD 
Patients and Haemodialysis patients and the available studies report no 
retro cochlear component and the reports on reversibility of hearing 
impairment remains equivocal. Hence, I intend to proceed this study in 
order to document the electrophysiological changes in BAEP Waveforms 
and to determine the reversibility of the BAEP changes after renal 
transplantation. 
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REVIEW OF LITERATURE 
An Evoked potential is an electrical potential recorded from the 
nervous system of a human following a brief stimuli. Such potentials are 
useful for electro diagnosis and monitoring. Signals can be recorded from 
the cerebral cortex, brainstem & spinal cord on the peripheral nerves. 
Research History: 
 In 1967, Sohmer & Feinmesser54 were the first to record Auditory 
Brainstem Responses with surface electrodes. 
In 1971 Jewett & Williston55 described BAEP and interpreted the 
Absolute and Inter peak latencies. 
It was Lugigalvani who discovered the good conducting property 
of nerves in the year 1971. 
In 1833, The Techniques of electrical stimulation in a 
neuromuscular disease was discovered by Duchne. 
In 1977 Selters and Brackman56 produced landmark findings on 
prolonged Interpeak latency in tumour cases. 
1975, Hecox and Galambos57 pointed out that ABR could be used 
for estimating the hearing threshold in adults and infants. 
In the ARIC Study by Bash LD1, Coresh et al ,it was discussed and 
compared the several definitions of incident chronic kidney disease by 
means of incidence, agreement and risk factors. 
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Hsc CY, Chertow GM3 et al discussed the  issues that define the 
prevalence of CRI which included the laboratory differences in 
ser.creatinine assays, within person measurement errors in s.cr & 
variations among different demographic groups. 
Coresh J, Astor BC4 et al studied that errors in caliberation make 
little difference in estimating severely decreased GFR (<30 ml/min/1.73 
m2), but in higher GFRs, they produce larger difference. 
Murthy K, Stevens LA5 made a study & concluded that 
recaliberation of serum creatinine assays improved the accuracy of GFR 
estimation using MDRD study though it was not practical for all clinical 
laboratories. 
Coresh J, Selvin E6 et al studied that prevalence of CKD in united 
states in 1999-2004 was higher compared to 1988-1994 which was 
attributed to the increased prevalence of DM &HT. 
Coresh J, Astor BC7 et al in their study analysed kidney function & 
damage & stages of CKD which was estimated from calibrated serum. 
creatinine level, spot urine albumin level, age, sex & race. 
Jeon HG, Lee JW8, et al made a study & concluded that nephron 
sparing surgery for small renal mass should be attempted to prevent CKD 
in all eligible patients especially those with diabetes. 
Schmitz PG, Kasske9 et al examined the effects of 30 week 
enalapril treatment on the development of glomerular disease in obese 
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zucker rats. It was concluded that there could be a possible restriction of 
glomerular growth. 
Park SK, Kang SK10 Suggested that obesity & hyperinsulinemia 
which are commonly associated with type II Diabetes can also be 
associated with glomerular capillary hypertension. 
Chen J, Muntner P11 et al in their study suggested that metabolic 
syndrome is an important risk factor for CKD. 
Zatz, Meyer TW12 et al made a study to indicate that metabolic 
disorder seen in stable moderately hyperglycemic diabetic rats does not 
lead to glomerulopathy as long as elevation in glomerular pressures are 
prevented. 
Matsushita, Veldem13 et al studied the quantitative data for use of 
both kidney measures for risk assessment & definition and staging of 
CKD. 
Hunsicker LG, Greene T14 et al examined the effects of dietary 
protein restriction & strict blood pressure control on the reduction  in 
GFR. 
Ataga KI, Orringer15 et al studied that Sickle cell anemia and 
related hemoglobinopathies are associated with a large spectrum of renal 
abnormalities like impaired urinary concentrating ability, defects in 
urinary acidification and potassium excretion. 
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Mantarri M, Tiula E et al16 in their study suggested  that in addition 
to hypertension, serum lipids  also accelerate the decline in renal 
function. It was noted that subjects with elevated HDL had a rapid 
regression of renal function. 
Fox CS .Larson MG17 in their study indicated the fact that 
cardiovascular risk factors are associated with new onset kidney disease 
development. 
Eki K, Oshiro S18 et al made a study to prove that high levels of 
serum uric acid levels was a positive factor to correlate high ser. 
creatinine in the Japanese population.  
Bolignano D, Coppolino G19 et al in their study demonstrated that 
NGAL, a protein had a direct relation to proteinuria and inverse relation 
to residual renal function. 
Bolignano D, Coppnolino G 20 et al in their study stated that a 
stress protein –NGAL, plays a vital role in the pathophysiology of 
diabetic nephropathy. 
Halim JM, Giraudeau B21 et al did a study to illustrate the fact that 
chronic smokers, despite moderate smoking develop irreversible 
proteinuria. 
Shankar K, Klein R22, et al performed a cross sectional study to 
state that smoking along with consumption of alcohol per day is 
associated with chronic kidney disease. 
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Perneger TV, Klag MJ23 et al, did a cross sectional study to throw 
lights over a neglected risk factor i.e lifetime use of addictive drugs like 
cocaine and heroin were increasingly related with ESRD. 
Jaffe JA, Kimmel PL24 studied that cocaine use led to renal injury 
in the form of hemodynamic changes, glomerular degradation and 
oxidative stress. 
Muntner P, He J, Vupputuri25 et al in their study described the link 
between high lead exposure with renal damage and CKD. 
Lindeman RD, Tobin J26 et al did a longitudinal study to explain 
the rate of reduction in renal function with ageing by showing a 
significant rise in creatinine clearance. 
Kiberd BA, Clase CM28 et al in their study determined the effect of 
CKD on life expectancy & compared that with the impact of breast 
cancer and prostate cancer in women and men’s life expectancy 
respectively. 
Klag MJ, Randall BL29 et al, stated that high blood pressure and 
low socioeconomic status are the reasons for a four fold increase in CKD 
in African American men. 
Freedman BJ, Volkova NV30 et al, did a population based 
screening to make physicians aware of screening the family members to 
slow down the rate of growth of CKD. 
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Hostetter TH, Olson JL31 et al in their study demonstrated the 
changes in glomerular hemodynamics after renal ablation & 
hyperfiltration of a single nephron led to maladaptive consequences by 
glomerular damage. 
Zatz R, Dunn BR32 et al in their study with two groups of diabetic 
rats, noticed the increase in weight of the kidney, GFR and plasma flow 
in both groups. One group of diabetic rats which were not treated with an 
ACE inhibitor enalapril showed structural abnormalities. 
Keller G, Zimmer G 33 et al Proposed the fact that diminished 
number of nephrons contribute to primary hypertension 
Mcnamara BJ, Diouf B34 et al stated decrease in glomerular 
number & a large volume glomeruli increase the risk for renak 
hypertension in adult life. 
Ataga KJ, Orringer EP 35 et al studied sickle cell anaemia & other 
Hemoglobinopathies are associated with renal abnormalities which 
included defects in concentrating urine, excreting potassium & the 
function of proximal tubule is supranormal i.e there is increased 
creatinine secretion with phosphorous reabsorption. 
Steffes MW, Brown DM 36 et al  did a study in control rats and rats 
which were induced diabetes with sttreptozocin. Both groups underwent 
unilateral nephrectomy. It was noticed after 3 to 4 months of surgery, 
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there was a marked thickening of the mesangial matris with deposition of 
IgG & C3 
Khadra MH, Pickard RS37 et al did a prospective analysis of 1930 
patients with hematuria and proved that renal tumours can be detected by 
combined use of Ultrasound and IVP & not by cystoscopy alone. 
in the diabetic rats. 
Karl Tryggvason, Jankko Patrakka38 et al in their study concluded 
that patients with persistent microscopic hematuria develop thin basement 
membrane nephropathy. 
S.Tian, E.Kusano40 et al in their study suggested that measuring 
Cystatin C in both urine & serum is useful to estimate a mild decrease in 
GFR. It is also a marker for indicating the removal rate of a protein with 
low molecular weight &various types of flux membranes used in HD 
 Silkensen J, Kasiske BL41 et al studied the Laboratory assessment 
of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, 
ed. Brenner and Rector’s the kidney. Philadelphia: Saunders; 2004:1107-
1150. 
Sanger J, Kramer EL42 et al did a study on Radionuclide 
quantitation of renal function. Urol Radiol. 1992;14:69-72. 
Johnson WJ, Hagge WW, Wagoner RD37, et al. narrated the effects 
of urea loading in patients with far-advanced renal failure. Mayo Clin 
Proc. 1972;47:21-29. 
  
 
35 
Kraus LM, Kraus AP44 et al formulated a study to prove 
carbomylated molecules influence the fate of non-carbomylated 
molecules by blocking, enhancing or getting excluded from the metabolic 
pathways. Urea derived cyanate contribute to the toxic manifestations of 
uremia. 
Nagata Y,Akino T45 et al discussed in their study that elevation of 
plasma D aminoacid were observed in renal disease patients in proportion 
to the creatinine , β microglobulin levels and to the GFR. 
Abel J, Rowntree L, Turner B47. On the removal of diffusible 
substances from the circulating blood of living animals by dialysis. J 
Pharmacol Exp Ther. 1914;5:275-316. 
Haas G.48 Dialysis of the flowing blood in the patient. Klin 
Wochenschr. 1888;70:1923. 
Kolff WJ, Berk HT,49 Welle M, et al.The artificial kidney: a 
dialyser with a great area. 1944 [classical article]. J Am Soc Nephrol. 
1997;8:1959-1965. 
U.S. Renal Data System. USRDS 2010 Annual Data Report:50 
Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the 
United States. Bethesda, MD: National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases; 2010. 
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National Kidney Foundation. K/DOQI51 clinical practice guidelines  
and clinical practice recommendations for 2006 Updates: hemodialysis 
adequacy, peritoneal dialysis adequacy, and vascular access. Am J 
Kidney Dis. 2006;48(suppl 1):S1-S322. 
Brescia MJ, Cimino JE, Appel K52, et al did a study on Chronic 
hemodialysis using venipuncture and a surgically created arteriovenous 
fistula. N Engl J Med. 1966;275:1089-1092. 
Antoniou GA53, et al did a meta analysis & found out the 
occurrence of radial cephalic fistula failure in elderly patients which were 
less in the proximal brachiocephalic fistulas. 
Sreedhara R, Himmelfarb J54 et al discussed the. Impact of Anti-
platelet therapy in graft thrombosis: results of a prospective, randomized, 
double-blind study. Kidney Int. 1994;45:1477-1483 
Dixon, Beck55 et al in their study discussed that those patients who 
received dipyridamole & aspirin therapy after a new arteriovenous graft 
for hemodialysis access showed significant reduction in the occurrence of 
graft stenosis. 
Trakarnvanich T56 et al, discussed the efficacy of single-needle 
versus double-needle hemodialysis in chronic renal failure. J Med Assoc 
Thai. 2006;89(suppl 2):S196-S206. 
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Murray JE, Merrill JP58,et al made a study on kidney 
transplantation between 7 pairs of identical twins. Ann .surg. 
1958;148;35359. 
Cohen J, Rees AJ, Williams.59 et al did a  Prospective randomised 
control trial of perioperative antibiotic prophylaxis in renal 
transplantation .J hosp infect. 1988;11;357-363. 
Newer MR, Aminoff 64et al discussed the recommended standards 
for BAEP and submitted in the IFCN committee in the year 1994. 
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AIM AND OBJECTIVE 
To Evaluate Brainstem Auditory Evoked potential in chronic 
Kidney disease, Hemodialysis and Renal transplantation patients. 
OBJECTIVE:  
A) To document the electrophysiological changes in BAEP 
waveforms. 
 B) To determine the reversibility of BAEP changes after Renal 
Transplantation.  
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MATERIALS AND METHODS 
This study was conducted at the Department of Physiology in 
Kilpauk Medical College, Chennai. 
STUDY DESIGN  
Observational study. 
SUBJECT SELECTION   
Total sample size-80, controls-20,CKD Patients -20,Hemodialysis 
patients-20,Renal transplantation patients-20. 
INCLUSION CRITERIA 
1. Patients diagnosed to have Chronic kidney disease in the 
department of Nephrology with  eGFR <60 with duration more 
than 3 months. 
2. Chronic Kidney disease patients undergoing hemodialysis for more 
than one month in the department of Nephrology, KMC. 
3. Chronic Kidney disease patients who underwent Renal 
transplantation in the department of Nephrology, KMC. 
4. Male &female >18-70 years 
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EXCLUSION CRITERIA   
 Ischemic heart disease. 
 Cerebrovascular disease 
 Alcoholism. 
 Any neurological disease 
 Previous history of Hearing impairment 
 Alport syndrome 
CONTROLS 
Healthy volunteers who are age and sex matched were chosen as 
controls. 
SCREENING PROCEDURES 
 Patients who qualify under the inclusion criteria will be enrolled in 
 the study (Appendix A). 
 Blood pressure. 
 Height. 
 Weight. 
 Brief history to rule out IHD, diabetes, hearing impairment, 
 alcoholism, drug intake (Appendix B). 
 General clinical examination (Appendix B). 
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CONSENT     
A written informed consent was obtained from patients & controls 
after explaining the procedure and its significance in their vernacular 
language (Appendix F).  
EQUIPMENT DETAILS   
Brainstem auditory evoked potentials studies were carried out on a 
computerized Nerve conduction testing equipment: Medicaid, 
computerized physiolab, Neuroperfect plus. 
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ETHICAL CONSIDERATIONS 
Institutional Ethical committee approval was obtained from 
Kilpauk medical college Chennai -10. 
The settings were  as follows: 
STIMULUS PARAMETER; 
• Click stimulus having intensity 70 db, was presented to both ears 
monoaurally. During stimulation of one ear, the other ear was 
masked by 40 db sound. A total of 2000 stimulations generated by 
passing 0.1 millisecond square pulse through shielded headphones 
with alternating polarity were applied on both ears monoaurally. 
Stimulus were at the rate of 11.1/sec. 
 *filters : 
 1. low : 100 Hz 
          2.  high : 3 KHz 
Stimulus polarity   
 Two types of clicks were produced. 
 One, moving the earphone diaphragm away from the eardrum 
 (rarefaction click). 
 The other moving it in the opposite direction (condensation or 
 compression click). 
In this study, stimulus with rarefaction click is given. 
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Recording electrodes   
 The volume-conducted evoked responses are picked up from scalp 
by electrodes. Two electrodes were attached, one to right mastoid 
and other to left one as ground electrode to forehead, termed as Fz
 Recommended montage for BAEP : 
.  
All the electrodes were pluged to the junction box. Skin-to-
electrode impedance was monitored and kept below 5 kΩ. 
 CHANNEL 1: mastoid, designated as Ai and Ac respectively; one 
 reference  electrode on vertex , labeled as Cz; and Cz –A
 CHANNEL 2  : C
i  
Z  -  Ac
 GROUND      : F
  
Z
Fig : 8 BERA –Placement of electrodes 
  
 
 E – ear lobe recording, Cz – reference, Fz – ground electrodes 
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PREREQUISITES FOR THE STUDY 
A) The subjects were advised to clean and keep their head oil free. 
B) The research lab was made quiet and sound proof to the patients. 
C) Subjects were made to remove their ornaments. 
PROCEDURE: 
The BAEP Recording was done in the research laboratory, in the 
Department of physiology, Kilpauk medical college using Neuroperfect 
Plus-Medicaid Physiolab. In al subjects both right and left ears were 
tested separately. 
RECORDING OF BAEP-INSTRUMENT SETTING 
The requirements are  
1. Recording electrodes, 2.Amplifier and averager, 3. Electrode 
 paste, 4.Ear phone 
 Equipment set up; 
 Suggested Montage; 
1. Channel 1: Ai-Cz-Active electrodes 
2. Channel 2 : Ac -Cz -ipsilateral ear (Ai), contralateral ear (Ac) or 
mastoid process 
3. Ground : Fz-Reference electrode ;Cz, at vertex  
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Recording conditions  
1. Filter, low filter cut at 10-100 Hz ,high at 3000 Hz 
2. Amplification in the range of 2,00,000-5,00,000 
3. Sweep speed at 1 msec/division 
4. Electrode impedance kept below 5 kilo-ohms 
Stimulation options  
1. Sensitivity at 0.3uv/division 
2. 60 db sensory level, the point at which the individual barely 
 appreciates the stimulus. 
B.Steps 
1. The instrument is kept out of view of the subject. 
2. The subject is allowed to sit comfortably on a chair. 
3. Skin at the point where electrodes are placed is cleaned with spirit. 
4. Using a conducting jelly or electrode paste the active recording 
electrodes are placed on both the ears ipsilateral ear (Ai) and 
contralateral ear (Ac) or mastoid process as per 10-20 international 
system of EEG electrode placement ;the reference electrode is 
placed at the vertex i.e at Cz..the ground electrode is placed at Fz 
5. The electrodes are connected through the preamplifier to the 
cathode ray oscilloscope 
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6. A brief click stimulus, which is a square wave pulse of 0.1 msec 
duration is given. A click rate of 11-31 Hz is used mostly in 
clinical practice. 
7. The effects of click intensity is observed and the BAEP waveforms 
are compared with the normal. 
PARAMETERS STUDIED are the wave latencies I, II, III, IV & V 
and interpeak latency I-III, I-V, and III-V…Total duration of recording 
the waveforms is within 10 msec of stimulus. Thus brainstem auditory 
evoked potentials are recorded from the ear and scalp in response to a 
brief auditory stimuli. The evoked potentials that appear following 
transduction of acoustic stimulus by ear cells create an electric signal that 
is carried to the cerebral cortex via the auditory pathway. 
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TABLE : 2 
ANTHROPOMETRIC MEASUREMENT OF CASES (CKD)  
WITH CONTROLS 
VARIABLES 
CASE –CKD (20) 
Mean +SD 
CONTROLS 
N=30 
P 
VALUE 
AGE (YRS) 49+ 12.73 31.60+9.95 0.000 
WEIGHT(KG) 58.65+ 7.6 63.37+11 0.242 
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TABLE :3 
ANTHROPOMETRIC MEASUREMENT OF CASES (HD)  
WITH CONTROLS 
VARIABLES 
CASE =HD (20) 
Mean +SD 
CONTROLS 
(N=30) Mean 
+_SD 
P VALUE 
AGE (YRS) 36.75+_ 15.3 31.60+ 9.9 0.502 
WEIGHT(KG) 58.05+_4.3 63.37+_11.8 0.822 
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TABLE: 4 
ANTHROPOMETRIC MEASUREMENT OF CASES (RT)  
WITH CONTROLS 
VARIABLES 
CASE =RT (20) 
Mean +SD 
CONTROLS 
(N=30) Mean 
+_SD 
P 
VALUE 
AGE (YRS) 45.15+_13 31.60+_9.9 0.002 
WEIGHT(KG) 61.20+_6.925 63.37+_11.8 0.822 
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TABLE : 5 
COMPARISON OF SERUM CREATININE IN CASES AND 
CONTROLS 
SERUM. 
CREATININE 
MEAN SD P VALUE 
CONTROLS 0.712 0.1228 <0.001 
CKD 6.325 1.3692 <0.001 
DIALYSIS 6.280 1.3621 <0.001 
RENAL 
TRANSPLANT 
1.130 0.4842 0.418 
 
‘P’ Value is significant for controls, CKD & HD patients. 
  
  
 
51 
TABLE: 6 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR- BETWEEN CHRONIC KIDNEY PATIENTS & CONTROLS 
 
LATENCIES 
CASE (CKD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.82+-0.24 1.75+-0.07 0.771 
II 2.87+_0.14 2.83+_0.15 0.889 
III 4.21+_0.31 3.98+_0.06 0.044 
IV 4.99+_0.47 5.08+_0.17 0.859 
V 5.61+_0.47 5.69+_0.17 0.902 
 
Absolute peak latency of III waveform is significantly prolonged 
with a ‘p’ value of 0.044. 
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FIG - 9 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR- BETWEEN CHRONIC KIDNEY DISEASE  
PATIENTS & CONTROLS 
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TABLE 7 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR-BETWEEN HEMODIALYSIS PATIENTS & CONTROLS 
LATENCIES 
CASE (HD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.98+_0.48 1.75+_0.07 0.013 
II 2.79+_0.22 2.83+-0.15 0.891 
III 3.72+_0.33 3.98+_0.06 0.020 
IV 5.02+_0.15 5.08+_0.17 0.961 
V 5.78+_0.29 5.69+_0.17 0.851 
 
Absolute peak latency of waves I & III are prolonged with a ‘p’ 
value of 0.013 & 0.020. 
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FIG - 10 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR- BETWEEN HEMODIALYSIS PATIENTS & CONTROLS 
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TABLE: 8 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR-BETWEEN RENAL TRANSPLANTATION  
PATIENTS & CONTROLS 
LATENCIES 
CASE (HD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.74+_0.08 1.75+_0.07 1.000 
II 2.78+_0.26 2.83+_0.15 0.749 
III 3.87+_0.45 3.98+_0.06 0.564 
IV 4.90+_0.64 5.08+_0.17 0.424 
V 5.61+_0.63 5.69+_0.17 0.898 
 
There is no significant prolongation of absolute peak latency. 
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FIG 11 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF RIGHT 
EAR- BETWEEN RENAL TRANSPLANTATION PATIENTS & 
CONTROLS 
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TABLE: 9 
COMPARISON OF INTER PEAK LATENCIES  OF RIGHT EAR-
BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
LATENCIES 
CKD 
PATIENTS 
CONTROL P VALUE 
I-III 2.39+_0.49 2.23+_0.10 0.604 
III-V 1.50+_0.35 1.70+-0.18 0.127 
I-V 3.89+_0.24 3.92+_0.22 0.991 
 
There is no significant prolongation of inter peak latencies.. 
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FIG 12 
COMPARISON OF INTER PEAK LATENCIES  OF RIGHT EAR-
BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
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TABLE 10 
COMPARISON OF INTER PEAK LATENCIES OF RIGHT EAR- 
BETWEEN HAEMODIALYSIS PATIENTS & CONTROLS 
 
LATENCIES 
CKD 
PATIENTS 
CONTROL P VALUE 
I-III 1.79+_0.68 2.23+_0.10 0.005 
III-V 2.15+_0.50 1.70+_0.18 0.000 
I-V 3.84+_0.52 3.92+_0.22 0.901 
  
There is significant prolongation of I-III & I-V interpeak latencies 
with ‘p’ value of 0.005 & 0.000. 
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FIG 13 
COMPARISON OF INTER PEAK LATENCIES OF RIGHT EAR-
BETWEEN HEMODIALYSIS  PATIENTS & CONTROLS 
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TABLE: 11 
COMPARISON OF INTER PEAK LATENCIES OF RIGHT EAR-
BETWEEN RENAL TRANSPLANTATION PATIENTS & 
CONTROLS 
INTERPEAK 
LATENCIES 
RT  
PATENTS 
CONTROL P VALUE 
I-III 2.13+-0.43 2.23+_0.10 0.604 
III-V 1.71 1.70+-0.18 0.127 
I-V 3.89+_0.24 3.92+_0.22 0.991 
 
There  is no significant prolongation of interpeak latencies. 
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FIG :14 
COMPARISON OF INTER PEAK LATENCIES OF RIGHT EAR-
BETWEEN RT PATIENTS & CONTROLS 
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TABLE:12 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF LEFT 
EAR-BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
LATENCIES 
CASE (CKD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.79+_0.06 1.74+_0.11 0.764 
II 2.96+-0.26 2.85+_0.20 0.248 
III 4.21+_0.31 3.98+_0.06 0.044 
IV 4.96+_0.28 4.99+_0.52 0.994 
V 5.79+_0.24 5.67+_0.58 0.717 
 
The absolute peak latency of waveform III is prolonged with ‘p’ 
value 0.044. 
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FIG :15 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF LEFT 
EAR-  BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
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TABLE: 13 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF LEFT 
EAR- BETWEEN HAEMODIALYSIS  PATIENTS & CONTROLS 
 
LATENCIES 
CASE (HD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.90+_0.36 1.74+_0.11 0.018 
II 2.82+_0.21 2.85+_0.20 0.946 
III 3.60+_0.38 3.93+_0.37 0.003 
IV 4.91+_0.35 4.99+_0.52 0.898 
V 5.80+_0.26 5.67+_0.58 0.661 
 
There is significant prolongation of absolute peak latency of 
waveform I & III. 
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FIG :16 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF LEFT 
EAR-BETWEEN  HAEMODIALYSIS  PATIENTS & CONTROLS 
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TABLE :14 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF LEFT 
EAR-BETWEEN RENAL TRANSPLANTATION   PATIENTS & 
CONTROLS 
LATENCIES 
CASE (HD) 
MEAN +_SD 
CONTROL 
MEAN+-SD 
P VALUE 
I 1.74+_0.07 1.74+_0.11 1.000 
II 2.87+_0.07 2.85+_0.20 0.974 
III 3.92+_0.23 3.93+_0.37 1.000 
IV 5.06 +_0.14 4.99+_0.52 0.894 
V 5.72+_0.26 5.67+_0.58 0.967 
 
There is no significant prolongation of Absolute peak latencies 
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FIG :17 
COMPARISON OF ABSOLUTE PEAK LATENCIES OF  LEFT 
EAR-BETWEEN RENAL TRANSPLANTATION  PATIENTS & 
CONTROLS 
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TABLE: 15 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR-
BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
INTERPEAK 
LATENCIES 
RT  
PATIENTS 
CONTROL P VALUE 
I-III 2.24+-0.19 2.18+_0.30 0.957 
III-V 1.74+_0.31 1.75+_0.24 0.999 
I-V 4.00+_0.22 3.93+_0.51 0.936 
 
There is no significant prolongation of interpeak latencies. 
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FIG :18 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR-
BETWEEN CHRONIC KIDNEY DISEASE PATIENTS & 
CONTROLS 
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TABLE :16 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR- 
BETWEEN HEMODIALYSIS    PATIENTS & CONTROLS 
 
INTERPEAK 
LATENCIES 
RT  PATIENTS CONTROL P VALUE 
I-III 1.78+_0.66 2.18+_0.30 0.003 
III-V 2.20+_0.37 1.75+_0.24 0.000 
I-V 3.84+_0.46 3.93+_0.51 0.881 
 
There is significant prolongation of interpeak latencies I-III & III-
V with a ‘p’ value of 0.003 & 0.000 
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FIG :19 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR-
BETWEEN HEMODIALYSIS    PATIENTS & CONTROLS 
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TABLE :17 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR-
BETWEEN RENAL TRANSPLANTATION   PATIENTS & 
CONTROLS 
INTERPEAK 
LATENCIES 
RT  
PATIENTS 
CONTROL P VALUE 
I-III 2.19+_0.25 2.18+_0.30 1.000 
III-V 1.80+_0.20 1.75+_0.24 0.931 
I-V 3.99+_0.27 3.93+_0.51 0..959 
 
There is no significant prolongation of interpeak latencies. 
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FIG :20 
COMPARISON OF INTER PEAK LATENCIES OF LEFT EAR- 
BETWEEN RENAL TRANSPLANTATION   PATIENTS & 
CONTROLS 
. 
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RECORDING OF BAEP WAVEFORMS 
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RECORDING OF BAEP WAVEFORM IN A SUBJECT. 
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RESULTS 
CONTROL GROUP 
There were 30 cases in the control group with average weight of  
60.3 +_11.8 and creatinine 0.712 ± 0.12. 
CHRONIC KIDNEY DISEASE GROUP  
There are 20 CKD   patients with an average weight of 58.65 +_7.6 
kg and creatinine 6.32 ± 1.36. 
HAEMODIALYSIS GROUP 
There are 20 patients who were on haemodialysis in the department 
of nephrology, KMC with an average weight of 50.05+_4.3 kg and 
creatinine 6.2 ± 1.34. 
RENAL TRANSPLANTATION GROUP 
There are 20 patients who were treated with renal transplantation 
with an average weight of 60.20 +_6.9 kg and creatinine 1.13 ± 0.48. 
CKD patients were graded on the basis of Creatinine and Gfr and 
the average values of BAEP with Absolute and Inter peak latencies were 
recorded and given in table 6,9,12 & 15. 
The average value of Absolute peak latency and Inter peak 
latencies of HD patients were recorded and are given in table  
7,10,13& 16. 
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The average value of Absolute peak latency and Inter peak 
latencies of RT patients were recorded and given in table 8, 11, 4 & 17. 
In Chronic kidney disease group, there was a significant increase in 
the latencies of wave, III and inter peak latencies did not vary 
significantly in both ears. 
In haemodialysis group there was a significant increase in the 
absolute peak latencies of I & III and inter peak latencies I-III, III-V in 
both the ears. 
In renal transplantation group there was no significant change in 
either the absolute or the inter peak latencies in both the ears. 
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DISCUSSION 
The aim of our study was to evaluate Brainstem Auditory Evoked 
potentials in Chronic Kidney Disease patients and patients on 
Haemodialysis and in those who have undergone Renal transplantation. 
Quic CA, Fish A65 Studied the relationship between Cochlea and 
Kidney and concluded that Cochlea and Kidney have the same 
physiological process, Active transport of fluid & electrolytes 
accomplished by  Stria  vascularis  and glomerulus. They also attributed 
the similar effect of certain medications (ototoxic  medication) on these 
two organs. 
Alder et al in their study demonstrated the fact that there is a 
significant inhibition of Na+K+ATP ase in the inner ear of guinea pigs 
which had uraemia. They also suggested an inverse correlation between 
serum  Creatinine  levels  and  Na+K+ATP ase  activity which is vital for 
maintaining the cationic gradients in the inner ear. Hence inhibition of 
this enzyme contributed  to   inner  ear  abnormalities in uremic patients. 
In this study there is prolongation of Absolute and Inter peak 
Latencies in both the ears of Haemodialysis patients compared to Chronic 
Kidney Disease patients who were not started on Haemodialysis. This 
correlates with the study done by Naderpour M, Mortazavi F et al, in 
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which abnormal ABR recordings were seen in patients with Chronic 
kidney disease who were on Haemodialysis  compared to  chronic kidney 
disease patients who were yet to start on Haemodialysis. 
The Present study  showed prolongation of Absolute Peak 
Latencies I & III and Inter peak latencies I-III, III-V in patients 
undergoing Haemodialysis which correlates with the study done by 
Aspris ak, Thodi  CD et al, who demonstrated the effects of chronic 
kidney disease on auditory function & changes in the auditory function 
following  haemodialysis. It was seen that the absolute latency of wave 
III and inter peak latencies III-V & I-III were significantly prolonged than 
in Chronic Kidney disease patients not on Haemodialysis .This may be 
due to marked biochemical  changes seen in CKD as this reverses after 
successful transplantation.  
Hoth S, Weber FN et al in their study pointed out that the small 
increase in the ABR recordings were due to the broadening of the excited 
area & its shifting towards a more apical position of the hair cell 
population. 
In this Study there is a highly significant improvement in hearing 
and Absolute & Inter peak latencies after successful renal 
Transplantation. This partially correlates with the study of Brain KS, 
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Chopra H et al who documented Brainstem evoked response audiometry  
in Chronic kidney disease patients who underwent Renal Transplantation. 
After transplantation, Compared with the pre-transplant values there was 
a significant improvement in the I, III V latencies and hence it was 
concluded that, there is a definite improvement in hearing and wave 
latencies after successful Renal Transplantation. 
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CONCLUSION 
 This study has documented BAEP Changes in CKD and HD  
patients. 
 The changes in BAEP Waveforms are in both cochlear and retro 
cochlear components of Auditory pathway. 
 The marked changes in BAEP Waveforms in patients undergoing 
Hemodialysis may reflect the intensity and fluctuation in biochemical 
changes related to CKD. 
 The reversal of BAEP changes after successful Renal 
transplantation throws light on the rehabilitatory potential of Renal 
transplantation on audiological dysfunction. 
 
LIMITATIONS OF MY STUDY 
 The value of biochemical markers of CKD on the day of recording 
BAEP Could have been recorded which would have helped in explaining 
the marked changes seen in patients under Hemodialysis. 
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ANNEXURE - A 
PATIENT DATA COLLECTION 
DEPARTMENT OF PHYSIOLOGY, KMC , CHENNAI. 
1.DATE  : 
2.TIME  : 
3.ID NO   : 
4.NAME  : 
5.AGE (yrs)  : 
6.GENDER   : 
7.HEIGHT(cm)  : 
8.WEIGHT(kg)  : 
9.ADDRESS  : 
10.OCCUPATION  : 
11.CONTACT NUMBER  : 
 
 
 
ANNEXURE -B 
BRIEF CLINICAL HISTORY & GENERAL CLINICAL 
EXAMINATION 
DEPARTMENT OF PHYSIOLOGY, GKMC , CHENNAI. 
NAME OF THE PATIENT : 
AGE : 
ID NO: 
S.no History / symptoms Yes no 
1. Chronic cough > 2 wks   
2. H/O loss of appetite   
3.  H/O loss of weight   
4. H/O diabetes   
5. H/O hypertension   
6. H/O alcohol intake   
7. H/O drug intake   
8. H/O any neurological disease or H/O treatment 
from neurologist 
  
9. H/O thyroid disorder or H/O drug intake for 
thyroid disorder 
  
GENERAL EXAMINATION : 
1.BP - 
2.HEART RATE - 
3.RESPIRATORY RATE - 
4.TEMPERATURE - 
5.ALERTNESS - 
6. ANAEMIA - 
7. CYANOSIS - 
8.PEDAL EDEMA - 
9.CLUBBING -  
10.JAUNDICE - 
11.CVS EXAMINATION : 
12.RS EXAMINATION  : 
13.CNS EXAMINATION : 
 
 
 
ANNEXURE - C 
MEASURES OF BAEP ANALYSIS 
 
WAVES Rt EAR- latency in 
milliseconds 
Lt EAR- latency in 
milliseconds 
1   
II   
III   
IV   
V   
I-III   
III-V   
I-V   
 
 
 
 
 
 
 
ANNEXURE - D 
PATIENT INFORMATION SHEET 
We are conducting a study on Evaluation of Brainstem auditory 
evoked potentials in Chronic Kidney Disease, Hemodialysis and Renal 
transplantation patients in the Department of Physiology, KMC,  
Chennai – 600 010.The purpose of this study is to diagnose subclinical 
involvement of auditory pathway in the concerned patients. We are 
selecting some patients and if you are found eligible for this study, we do 
the Brainstem auditory evoked potential test for you to assess the 
functional integrity of auditory pathways, which in anyway do not affect 
your treatment. The privacy of the patients in the research will be 
maintained throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. Taking part in this study is involuntary. You 
are free to decide whether to participate in this study or to withdraw at 
any time; your decision will not result in any loss of benefits to which 
you are otherwise entitled. The results of the special study may be 
intimated to you at the end of the study period or during the study if 
anything is found abnormal which may aid in the management.  
Signature of investigator     Signature of Participant   
Date : 
ANNEXURE - E 
INFORMED CONSENT FORM 
Title of the study : Evaluation of Brainstem auditory evoked potentials in 
chronic kidney disease Hemo dialysis and Renal transplantation patients.  
 Name of the participant :   Age    Sex : 
IP No: 
Name of the Principal investigator :  
Name of the Institution : Department of Physiology, Kilpauk Medical 
College, Chennai – 600 010.  
Documents of the informed consent  
I____________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been 
answered. I am over 18 years of age and, exercising my free power of 
choice, hereby give my consent to be included as a participant in 
“Brainstem auditory evoked potential in chronic kidney disease, 
hemodialysis and renal transplantation patients. 
1. I have read and understood this consent form and the information 
provided to me.  
2. I have had the consent document explained to me 
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the 
investigator. 
5. I have been informed the investigator of all the treatments I am 
taking or have taken in the past including any native (alternative) 
Treatment. 
6. I agree to cooperate with the investigator and I will inform her 
immediately if I suffer unusual symptoms.  
7. I have not participated in any research study in the past  
8. I am aware of the fact that I can opt out of the study at any time 
without having to given any reason and this will not affect my 
future treatment in this hospital.  
9. I am also aware that the investigator may terminate my 
participation in the study at any time, for any reason, without my 
consent.  
10. I hereby give permission to the investigators to release the inform 
obtained from me as result of participation in this study to the 
sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented.  
11. I have understood that my identity will be kept confidential if my 
date are publicly presented.  
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study.  
14. I am aware that if I have any question during this study, I should 
contact the investigator. By signing this consent form I attest that 
the information given in this document has been clearly explained 
to me and understood by me, I will be given a copy of this consent 
document.  
 
Signature & Date    

TURNITIN DIGITAL RECEIPT 
 
 
 
 
 
 
 
  

Sl.No. AGE GENDER
HEIGHT  
(cm)
WEIGHT 
(Kg)
S.CREATININ
E
BLOOD 
PRESSURE 
(mm Hg)
WAVE 1
WAVE 
2
WAVE 
3
WAVE 
4
WAVE 
5
WAVES 
1-3
WAVES 
3-5
WAVES 
1-5
WAVE 
1 WAVE 2
WAVE 
3
WAVE 
4
WAVE 
5
WAVES 
1-3
WAVES 
3-5
WAVES 
1-5
1 32 F 163 59 0.6 120/70 1.69 2.93 4 5.14 5.87 2.31 1.87 4.18 1.69 2.94 3.98 5.22 5.94 2.29 1.96 4.25
2 57 M 160 60 0.8 140/80 1.68 2.94 4.06 5.24 5.88 2.38 1.82 4.2 1.76 2.95 4.02 5.09 5.86 2.2 1.9 4.1
3 25 F 154 48 0.61 110/70 1.7 2.96 4.09 5.33 5.39 2.39 1.3 3.69 1.79 2.88 4.09 4.9 5.78 2.3 1.69 3.99
4 31 F 156 45 0.64 130/80 1.68 2.8 4.08 5.34 5.9 2.4 1.82 4.22 1.8 2.87 4.08 4.99 5.89 2.28 1.81 4.09
5 42 F 165 88 0.8 130/86 1.71 2.88 3.99 4.86 5.91 2.28 1.92 4.2 1.84 2.85 3.99 5.34 5.56 2.15 1.57 3.72
6 36 F 152 56 0.66 124/80 1.76 2.78 3.95 4.87 5.49 2.19 1.54 3.73 1.85 2.84 3.89 5.21 5.6 2.04 1.71 3.75
7 41 F 160 78 1 130/86 1.79 2.9 3.97 5.05 5.47 2.18 1.5 3.68 1.76 2.91 3.9 4.97 5.66 2.14 1.76 3.9
8 53 F 160 54 0.92 120/86 1.68 2.95 3.89 5.02 5.54 2.21 1.65 3.86 1.69 2.93 3.94 4.98 5.76 2.25 1.82 4.07
9 33 F 174 74 0.8 130/70 1.85 2.96 3.9 5.14 5.52 2.05 1.62 3.67 1.66 2.84 3.97 5.09 5.9 2.31 1.93 4.24
10 35 F 176 76 0.68 120/80 1.88 2.89 3.99 5.32 5.65 2.11 1.65 3.77 1.7 2.82 3.99 5.26 5.8 2.29 1.81 4.1
11 26 F 174 60 0.6 110/66 1.68 2.88 3.91 4.99 5.66 2.23 1.75 3.98 1.81 2.86 3.89 5.31 5.89 2.08 2 4.08
12 18 M 176 75 0.64 120/80 1.78 2.78 3.9 5.06 5.76 2.12 1.86 3.97 1.74 2.88 4.02 4.98 5.76 2.28 1.74 4.02
13 23 M 175 80 1 134/84 1.76 2.91 3.9 4.97 5.66 2.14 1.76 3.9 1.67 2.82 4.03 5.32 5.56 2.36 1.53 3.89
14 18 F 166 62 0.6 130/82 1.69 2.93 3.94 4.98 5.76 2.25 1.82 4.07 1.69 2.94 4.07 5.27 5.67 2.38 1.6 3.98
15 33 M 170 70 0.68 110/76 1.66 2.84 3.97 5.09 5.9 2.31 1.93 4.24 1.3 1.85 2 2.35 2.65 0.7 0.65 1.35
16 34 F 166 50 0.66 110/60 1.7 2.82 3.99 5.26 5.8 2.29 1.81 4.1 1.85 2.96 4.05 4.94 5.9 2.2 1.85 4.05
17 20 M 168 56 0.6 120/80 1.81 2.86 3.89 5.31 5.89 2.08 2 4.08 1.7 2.88 4.1 4.86 5.87 2.4 1.77 4.17
18 42 F 156 56 0.7 120/80 1.7 2.88 4.1 4.86 5.87 2.4 1.77 4.17 1.8 2.84 3.99 4.99 5.74 2.19 1.75 3.94
19 46 M 170 72 0.6 120/80 1.8 2.84 3.99 4.99 5.74 2.19 1.75 3.94 1.82 2.8 3.92 5.03 5.61 2.1 1.69 3.79
20 25 F 163 61 0.8 120/80 1.88 2.79 3.91 5.33 5.93 2.03 2.02 4.05 1.85 2.79 3.93 4.89 5.71 2.08 1.78 3.86
LEFT EAR -LATENCY in millisecondsRIGHT EAR -LATENCY in milliseconds
Control Group
MASTER SHEET
CKD Group
Sl.
NO. AGE GENDER
HEIGHT  
(cm)
WEIGHT 
(Kg)
S.CREATI
NINE
BLOOD 
PRESSURE 
(mm Hg)
WAVE 
1
WAVE 
2
WAVE 
3
WAVE 
4 WAVE 5
WAVES 
1-3
WAVES 
3-5
WAVES 
1-5 WAVE 1 WAVE 2 WAVE 3 WAVE 4 WAVE 5
WAVES 
1-3
WAVES 
3-5
WAVES 
1-5
1 57 M 160 60 6 140/90 1.72 2.9 4.02 5.12 5.89 2.3 1.87 4.17 1.7 2.82 4.51 5.01 5.55 2.31 1.04 3.85
2 52 F 168 66 4.8 130/86 2.8 3.08 3.38 4.6 5.88 0.58 2.5 3.08 1.79 2.9 4 5.1 5.59 2.21 1.59 3.8
3 35 M 172 70 7.2 140/82 1.69 2.92 4.47 5.36 5.79 2.78 1.32 4.1 1.8 2.9 4.03 4.99 5.52 2.23 1.49 3.72
4 43 F 166 60 5 130/90 1.7 2.86 4.07 5.33 5.94 2.37 1.87 4.24 1.8 3.2 4.2 4.99 5.95 2.42 1.73 4.15
5 68 F 150 58 4.2 120/86 1.72 2.92 4.51 4.89 5.89 2.79 1.38 4.17 1.75 3.2 4.32 5 5.96 2.57 1.64 4.21
6 63 M 168 60 7.8 140/78 1.75 2.84 3.99 4.88 5.65 2.24 1.66 3.9 1.79 2.97 3.91 4.99 5.51 2.12 1.6 3.72
7 23 M 170 68 8 156/90 1.77 2.89 4.5 5.09 5.6 2.73 1.1 3.83 1.75 2.8 3.95 4.89 5.5 2.2 1.55 3.75
8 64 M 160 56 6.8 160/88 1.69 2.94 4.51 5.06 5.6 2.82 1.09 3.91 1.82 2.85 4 5 5.49 2.13 1.49 3.67
9 48 F 155 50 6.6 140/74 1.79 2.99 3.97 5.1 5.55 2.18 1.58 3.76 1.79 3.14 4.27 5.3 5.97 2.48 1.7 4.18
10 35 M 156 52 9 146/80 1.79 2.97 3.91 4.99 5.51 2.12 1.6 3.72 1.84 3.1 4.35 5.1 5.95 2.51 1.6 4.11
11 40 F 158 54 6.6 130/80 1.88 2.95 4.5 5.19 5.77 2.62 1.27 3.89 1.8 2.9 4.03 4.99 5.52 2.23 1.49 3.72
12 45 M 160 61 7.2 120/80 1.66 2.88 3.99 5.27 5.59 2.33 1.6 3.93 1.88 3.14 4.12 4.93 5.99 2.24 1.87 4.11
13 56 F 154 50 4.7 150/86 1.79 2.78 3.94 5.33 5.66 2.15 1.72 3.87 1.79 2.98 4.17 4.9 6 2.38 1.83 4.21
14 34 M 168 56 6.4 140/86 1.83 2.9 4.46 5.1 5.96 2.63 1.5 4.13 1.8 3.2 4.22 4.99 5.95 2.42 1.73 4.15
15 48 F 160 60 5.6 154/90 1.88 2.95 4.5 5.19 5.77 2.62 1.27 3.89 1.7 2.9 3.9 5.27 5.45 2.2 1.55 3.75
16 68 M 164 78 3.8 160/94 1.8 2.82 4.4 4.99 5.6 2.6 1.2 3.8 1.74 3 3.9 5.36 6 2.16 2.2 4.26
17 66 F 158 54 5.8 158/86 1.82 2.34 4.06 4.99 5.59 2.24 1.53 3.77 1.66 2 3.5 4 5.8 1.84 2.3 4.14
18 50 M 150 48 6.2 154/70 1.81 2.9 4.06 3.13 3.71 2.25 1.65 3.9 1.86 3 3.8 4.6 5.9 1.94 2.1 4.04
19 45 F 156 50 8 160/80 1.8 2.84 4.5 5.1 5.65 2.7 1.15 3.85 1.88 3 4 4.8 6 2.12 2 4.12
20 40 M 165 62 6.8 154/70 1.7 2.82 4.51 5.01 5.55 2.81 1.04 3.85 1.9 3.1 3.98 5 6.2 2.08 2.22 4.3
RIGHT EAR -LATENCY in milliseconds LEFT EAR -LATENCY in milliseconds
Sl.
NO. AGE GENDER
HEIGHT  
(cm)
WEIGHT 
(Kg)
S.CREATI
NINE
BLOOD 
PRESSUR
E (mm Hg)
WAVE 1
WAVE 
2 WAVE 3
WAVE 
4 WAVE 5
WAVES 
1-3
WAVES 3-
5
WAVES 
1-5
WAVE 
1 WAVE 2 WAVE 3 WAVE 4
WAVE 
5
WAVES 
1-3
WAVES 3-
5
WAVES 
1-5
1 57 M 160 56 4 160/90 1.5 2.6 3.7 5 5.8 2.2 2.1 4.3 1.4 2.7 3.8 5.1 5.9 2.2 2.1 4.3
2 62 F 156 50 7.6 120/80 1.8 2.9 4.03 4.99 5.52 2.23 1.49 3.72 1.9 3 4.04 5 5.62 2.14 1.58 3.92
3 50 M 160 60 4 110/78 2.2 2.72 3.08 5.45 5.98 1.78 2.9 3.78 1.9 2.08 3.05 4.6 5.72 1.15 2.67 3.82
4 25 F 156 56 6 120/80 2.05 2.5 3.4 4.95 5.65 1.45 2.25 3.6 1.82 2.6 3.52 4.85 5.8 1.7 2.28 3.98
5 31 F 163 60 6.2 110/90 1.87 2.8 3 5 5 1.13 2.8 3.93 2.84 2.8 3 4.02 5.88 0.16 2.88 3.04
6 25 F 158 56 4.8 120/90 2.9 2.9 3.25 4.72 5.89 0.35 2.64 2.99 2.38 2.8 3 4.75 5.8 0.62 2.8 3.42
7 16 M 168 60 5.4 130/80 2.88 2.72 3.72 5.08 5.9 0.84 3.08 3.02 1.85 2.98 3.7 5.38 5.82 1.85 2.12 3.87
8 18 M 170 62 6.6 130/88 2.7 3 3.6 5 5.6 0.9 2 2.9 1.8 2.8 3.2 4.8 5.4 1.4 2.2 3.6
9 20 F 166 62 7 140/92 2.94 3 3.4 4.9 6 0.46 2.6 3.06 2.76 3 3.44 4.4 5.88 1.04 2.44 3.12
10 35 M 158 54 7.8 150/92 1.4 2.8 3.6 5 6.2 2.2 2.6 4.8 1.5 2.9 3.7 5.1 6.3 2.2 2.6 4.8
11 23 F 164 58 9.6 140/90 2 2.9 3.8 5 6.4 1.8 2.6 4.4 2 2.8 3.8 4.94 6 1.8 2.2 4
12 45 M 166 57 4.5 150/80 1.76 2.78 3.95 4.87 5.49 2.19 1.54 3.73 1.85 2.84 3.39 5.21 5.6 2.04 1.71 3.75
13 56 M 162 56 5.8 146/82 1.68 2.05 3.89 5.02 5.54 2.21 1.65 3.86 1.7 2.82 3.99 5.26 5.8 2.29 2.29 4.1
14 40 F 150 48 7 150/82 1.6 2.8 4 4.9 6 2.4 2 4.4 1.86 2.8 3.54 5 6 2.68 2.46 4.14
15 60 M 155 58 6.6 140/86 1.7 2.8 3.99 4.99 5.79 2.29 1.8 4.09 1.8 2.9 4 5 5.89 2.29 1.8 4.09
16 56 M 168 65 5.4 158/90 1.69 2.94 3.98 5.22 5.94 2.29 1.96 4.25 1.86 3 3.8 5.5 6 1.94 2.2 3.14
17 28 F 167 65 6.6 150/86 1.76 2.95 4.02 5.09 5.86 2.2 1.9 4.1 1.6 3 4 4.6 5.8 2.4 1.8 4.2
18 34 F 156 56 7 150/82 1.76 2.91 3.9 4.97 5.66 2.14 1.76 3.9 1.72 2.92 4 5.04 6 2.28 2 4.28
19 32 M 160 60 6.7 148/90 1.74 2.88 4.02 4.98 5.76 2.28 1.74 4.02 1.8 2.6 3 4.6 5 1.2 2 3.2
20 22 M 162 62 7 150/86 1.69 2.94 4.07 5.27 5.67 2.38 1.6 3.98 1.7 3 4 5.1 5.8 2.3 1.8 4.1
RIGHT EAR -LATENCY in milliseconds LEFT EAR -LATENCY in milliseconds
Hemodialysis Group
Sl.No. AGE GENDER HEIGHT  (cm)
WEIGHT 
(Kg)
S.CREATI
NINE
BLOOD 
PRESSUR
E (mm Hg)
WAVE 
1
WAVE 
2 WAVE 3 WAVE 4 WAVE 5
WAVES 1-
3
WAVES 3-
5
WAVES 
1-5
WAVE 
1 WAVE 2 WAVE 3
WAVE 
4
WAVE 
5
WAVES 
1-3
WAVES 
3-5
WAVES 1-
5
1 31 M 175 75 1 120/80 1.65 1.72 2 2.25 3 0.35 1 1.35 1.65 2.86 3.93 5.23 5.46 2.32 1.43 3.85
2 46 M 170 67 1.2 130/80 1.7 2.8 4 4.96 5.8 2.3 1.96 4.1 1.8 2.9 4.09 5.07 5.86 2.29 1.77 4.06
3 25 M 172 70 2 126/88 1.86 2.9 3.84 5 5.8 2.14 1.96 4 1.81 2.96 3.89 4.9 5.87 2.08 1.98 4.06
4 30 F 167 66 0.6 120/80 1.76 2.76 3.9 5 5.69 2.14 1.79 3.93 1.8 2.88 3.9 5.24 5.9 2.1 2 4.1
5 43 F 156 56 0.78 110/70 1.8 2.8 4 4.8 5.5 2.2 1.5 3.7 1.66 2.86 3.92 5.3 5.79 2.26 1.87 4.13
6 52 F 160 60 0.66 100/80 1.8 2.9 3.9 5.19 5.78 2.1 1.88 3.98 1.68 2.78 3.98 4.94 5.87 2.3 1.89 4.19
7 43 F 166 56 1 120/80 1.66 2.8 3.9 5.14 5.77 2.3 1.87 4.11 1.67 2.79 4.04 4.99 5.95 2.37 1.91 4.28
8 57 M 168 68 1.4 110/80 1.86 2.9 3.88 4.94 5.76 2.02 1.88 3.9 1.7 2.8 4.06 4.97 5.87 2.36 1.81 4.17
9 68 F 158 56 1.5 110/70 1.85 2.83 4.05 5.08 5.97 2.2 1.92 4.12 1.8 2.9 3.99 5 5.88 2.19 1.89 4.08
10 63 M 170 72 1.6 120/80 1.79 2.73 4.07 4.94 5.63 2.28 1.56 3.84 1.65 2.77 3.9 4.99 5.45 2.25 1.55 3.8
11 58 M 166 60 1.8 110/86 1.8 2.9 4.04 5.2 5.79 2.24 1.75 3.99 1.85 2.89 3.99 5.06 5.55 2.14 1.56 3.7
12 55 M 158 57 0.63 120/80 1.8 2.9 3.99 5 5.98 2.19 1.19 4.18 1.69 2.93 4 5.14 5.87 2.31 1.87 4.18
13 60 M 165 65 0.64 120/70 1.77 2.76 3.97 4.86 5.45 2.2 1.43 3.68 1.68 2.94 4.06 5.24 5.88 2.38 1.82 4.2
14 45 M 168 66 0.68 110/76 1.66 2.87 3.94 5.26 5.76 2.28 1.82 4.1 1.7 2.96 4.09 5.33 5.89 2.39 1.8 4.19
15 52 M 158 56 1.6 110/80 1.69 2.94 4.07 5.27 5.67 2.38 1.6 3.98 1.79 2.9 3.97 5.05 5.47 2.18 1.5 3.68
16 35 F 162 60 2 120/80 1.66 2.84 3.97 5.09 5.9 2.31 1.93 4.24 1.71 2.88 3.99 4.86 5.91 2.28 1.92 4.2
17 31 F 154 54 0.62 110/70 1.76 2.92 3.88 4.96 5.64 2.12 1.76 3.86 1.78 2.78 3 4.84 5 1.22 2 3.22
18 25 F 158 50 1 120/80 1.56 2.84 4.08 4.96 5.66 2.52 1.58 4.1 1.85 2.96 3.9 5.14 5.52 2.05 1.62 3.67
19 28 M 162 54 1.2 110/70 1.79 2.79 3.94 5.22 5.86 2.15 1.92 4.07 1.8 2.94 3.8 5 6 2 2.2 4.2
20 56 F 156 56 0.68 110/70 1.66 2.67 3.89 4.92 5.72 2.23 1.83 4.06
RIGHT EAR -LATENCY in milliseconds LEFT EAR -LATENCY in milliseconds
Renal Transplantation Group
